Menu
Back to Journals » OncoTargets and Therapy » Volume 14
Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer
Authors Wang M, Xu T, Feng W, Liu J, Wang Z
Received 21 September 2020
Accepted for publication 8 March 2021
Published 7 April 2021 Volume 2021:14 Pages 2397—2415
DOI https://doi.org/10.2147/OTT.S283157
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Leo Jen-Liang Su
Mengwei Wang,* Tianwei Xu,* Wenyan Feng,* Junxia Liu, Zhaoxia Wang
Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhaoxia Wang
Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Jiangjiayuan Road 121#, Nanjing, People’s Republic of China
Tel +86-25-58509810
Fax +86-25-58509994
Email [email protected]
Abstract: Long noncoding RNAs (lncRNAs) are a class of RNA molecules that are longer than 200 nucleotides and cannot encode proteins. Over the past decade, lncRNAs have been defined as regulatory elements of multiple biological processes, and their aberrant expression contributes to the development and progression of various malignancies. Recent studies have shown that lncRNAs are involved in key cancer-related signaling pathways, including the Hippo signaling pathway, which plays a prominent role in controlling organ size and tissue homeostasis by regulating cell proliferation, apoptosis, and differentiation. However, dysregulation of this pathway is associated with pathological conditions, especially cancer. Accumulating evidence has revealed that lncRNAs can modulate the Hippo signaling pathway in cancer. In this review, we elaborate on the role of the Hippo signaling pathway and the advances in the understanding of its lncRNA-mediated regulation in cancer. This review provides additional insight into carcinogenesis and will be of great clinical value for developing novel early detection and treatment strategies for this deadly disease.
Keywords: lncRNAs, Hippo pathway, cancer, tumorigenesis, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.